Suboptimal Completion Rates, Adverse Events, Costs, Resource Utilization, and Cost Impact of Noncompletion in Oral Adjuvant Capecitabine–Based Chemotherapy in Patients With Early-Stage Colon Cancer
- 12 May 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (4), e215-e225
- https://doi.org/10.1016/j.clcc.2021.05.002
Abstract
No abstract availableKeywords
Funding Information
- Proteus Digital Health Inc
This publication has 33 references indexed in Scilit:
- Patients With Locally Advanced and Metastatic Colorectal Cancer Treated With Capecitabine Versus 5-Fluorouracil as Monotherapy or Combination Therapy With Oxaliplatin: A Cost ComparisonClinical Colorectal Cancer, 2010
- Oral systemic therapy: Not all "win-win"Indian Journal of Medical and Paediatric Oncology, 2010
- Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancerCancer, 2009
- Costs Associated with Capecitabine or 5-Fluorouracil Monotherapy after Surgical Resection in Patients with Colorectal CancerOncology, 2009
- Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukesʼ C Colon CancerClinical Drug Investigation, 2008
- Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patientsBritish Journal of Cancer, 2007
- Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialBritish Journal of Cancer, 2006
- A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancerAnnals of Oncology, 2005
- Capecitabine as Adjuvant Treatment for Stage III Colon CancerThe New England Journal of Medicine, 2005
- Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancerEuropean Journal of Cancer, 2002